The Role of Genomics and Proteomics: Technologies in Studying Non-alcoholic Fatty Liver Disease

Ancha Baranova; Lance Liotta; Emanuel Petricoin; Zobair M. Younossi

doi:10.1016/j.cld.2007.02.003

The Role of Genomics and Proteomics: Technologies in Studying Non-alcoholic Fatty Liver Disease

Ancha Baranova, Lance Liotta, Emanuel Petricoin, Zobair M. Younossi^*

^*Corresponding author for this work

Surgery

Research output: Contribution to journal › Review article › peer-review

27 Scopus citations

Abstract

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are examples of complex diseases accompanied by changes in the expression of thousands of genes and a plethora of proteins encoded by these genes. Before the era of high-throughput analysis, typical translational research initiatives, aimed at defining the molecular targets for complex diseases, were performed on gene-by-gene basis. Innovative technologies, such as expression microarrays, mass spectromety, and reverse proteomics, now allow investigators to reveal complex patterns of the expression of biologically active molecules. For this reason, high-throughput approaches may be well suited for studies designed to untangle the molecular basis of the chronic liver diseases such as NAFLD.

Original language	English
Pages (from-to)	209-220
Number of pages	12
Journal	Clinics in Liver Disease
Volume	11
Issue number	1
DOIs	https://doi.org/10.1016/j.cld.2007.02.003
State	Published - Feb 2007

Access to Document

10.1016/j.cld.2007.02.003

Cite this

@article{0c7f92e4604b43db81c4d9bab5c9e041,

title = "The Role of Genomics and Proteomics: Technologies in Studying Non-alcoholic Fatty Liver Disease",

abstract = "Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are examples of complex diseases accompanied by changes in the expression of thousands of genes and a plethora of proteins encoded by these genes. Before the era of high-throughput analysis, typical translational research initiatives, aimed at defining the molecular targets for complex diseases, were performed on gene-by-gene basis. Innovative technologies, such as expression microarrays, mass spectromety, and reverse proteomics, now allow investigators to reveal complex patterns of the expression of biologically active molecules. For this reason, high-throughput approaches may be well suited for studies designed to untangle the molecular basis of the chronic liver diseases such as NAFLD.",

author = "Ancha Baranova and Lance Liotta and Emanuel Petricoin and Younossi, {Zobair M.}",

year = "2007",

month = feb,

doi = "10.1016/j.cld.2007.02.003",

language = "English",

volume = "11",

pages = "209--220",

journal = "Clinics in Liver Disease",

issn = "1089-3261",

publisher = "W.B. Saunders",

number = "1",

}

TY - JOUR

T1 - The Role of Genomics and Proteomics

T2 - Technologies in Studying Non-alcoholic Fatty Liver Disease

AU - Baranova, Ancha

AU - Liotta, Lance

AU - Petricoin, Emanuel

AU - Younossi, Zobair M.

PY - 2007/2

Y1 - 2007/2

N2 - Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are examples of complex diseases accompanied by changes in the expression of thousands of genes and a plethora of proteins encoded by these genes. Before the era of high-throughput analysis, typical translational research initiatives, aimed at defining the molecular targets for complex diseases, were performed on gene-by-gene basis. Innovative technologies, such as expression microarrays, mass spectromety, and reverse proteomics, now allow investigators to reveal complex patterns of the expression of biologically active molecules. For this reason, high-throughput approaches may be well suited for studies designed to untangle the molecular basis of the chronic liver diseases such as NAFLD.

AB - Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are examples of complex diseases accompanied by changes in the expression of thousands of genes and a plethora of proteins encoded by these genes. Before the era of high-throughput analysis, typical translational research initiatives, aimed at defining the molecular targets for complex diseases, were performed on gene-by-gene basis. Innovative technologies, such as expression microarrays, mass spectromety, and reverse proteomics, now allow investigators to reveal complex patterns of the expression of biologically active molecules. For this reason, high-throughput approaches may be well suited for studies designed to untangle the molecular basis of the chronic liver diseases such as NAFLD.

UR - http://www.scopus.com/inward/record.url?scp=34249706743&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2007.02.003

DO - 10.1016/j.cld.2007.02.003

M3 - Review article

C2 - 17544980

AN - SCOPUS:34249706743

SN - 1089-3261

VL - 11

SP - 209

EP - 220

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

IS - 1

ER -

The Role of Genomics and Proteomics: Technologies in Studying Non-alcoholic Fatty Liver Disease

Abstract

Access to Document

Fingerprint

Cite this